The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...

MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –– Up to 30% of people with membranous nephropathy progress to ...

Mizoram’s HIV prevalence stands at 2.74 per cent - 13 times higher than the national average - prompting the state government ...

A mother who attributed her severe lower back pain to an old mattress was left devastated by a diagnosis of aggressive ...

A man’s estate is suing two off-Strip resorts for wrongful death after contracting Legionnaires’ disease. Gary Curtis Jones’ estate is suing the South Point casino-hotel and The Grandview at Las Vegas ...

Moffitt Cancer Center is now out of reach for many with Aetna Medicare Advantage HMO and PPO plans, and it will soon be the same for Humana Medicare Advantage HMO and PPO plans.

The Night Agent,” one of Netflix’s most-watched shows, is back for Season 3. Here’s the exact time it premieres and what to ...

ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...

Prime members can enjoy a steep 51% off Medicube's viral toner pore pads. This limited-time deal brings the K-beauty product ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

Innovent Biologics begins patient dosing in phase 3 study of IBI354 for first line treatment of HER2-positive breast cancer: San Francisco, US Monday, February 16, 2026, 11:00 Hrs ...